The bispecific antibody therapeutics market is estimated to be worth USD 6.9 billion in 2030, predicts Roots Analysis
Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target’ artificially engineered drugs have generated significant enthusiasm within the medical science community
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:
A detailed assessment of the current market landscape of drug developers engaged in the development of bispecific antibody therapeutics.
A comprehensive analysis of novel technology platforms that are either currently available or being developed for the generation of bispecific antibody therapeutics.
Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics.
Key takeaways from the bispecific antibody therapeutics pipeline.
An analysis of the initiatives of big biopharma players engaged in this domain.
An analysis of recent partnerships and collaboration agreements inked in bispecific antibody therapeutics domain.
A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies.
A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics.
A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies.
A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Cytokines Retargeting / Neutralization
Dual Ligands Blocking
T-cell Retargeting / Activation
CD3 x CD19
CD30 x CD16A
Factor IXa x Factor X
IL-1α x IL-1β
IL-13 x IL-4
IL-17A x Albumin
IL-17A x IL-17F
Psl x PcrV
TNF-α x HAS
VEGF-A x ANG2
Target Disease Indication
Mechanism of Action
Key Geographical Region
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
Martin Steiner (Chief Executive Officer, Synimmune)
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at firstname.lastname@example.org